Profil des utilisateurs d’anti-inflammatoires non stéroïdiens

This publication has 8 references indexed in Scilit:

• Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case–control study
  Arthritis Research & Therapy, 2005
• Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database
  European Journal of Clinical Pharmacology, 2004
• Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
  Gut, 2003
• Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
  Gastroenterology, 2003
• Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data
  Rheumatology, 2003
• COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
  The Lancet, 2002
• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation
  Archives of internal medicine (1960), 2000